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INTRODUCTION 
“The pathological curiosity of one day becomes in its proper time a common place condition at 
a later time”.
Sir Harvey Cushing 
Meningiomas were once considered a complex and diverse group of neoplasms in view of their 
varied histological patterns. Over the years these morphologically different tumours have been studied 
in detail and the mysteries of their origins unraveled.
The term “meningioma” was coined by Sir Harvey Cushing, the most revered neurosurgeon of 
the 20th century. But as early as 1614 Felix Plater removed a brain tumor at autopsy which he described 
accurately. The neoplasm was in all probability a meningioma. The first brain tumour  reported from 
the United States also happens to be a meningioma.
In 1835, Professor Peccholi, Professor of Surgery and Operating Medicine from the University 
of Siena operated on a dural based tumour at the occiput which he described as a “fungus of the dura 
mater”.  Over  a  period  of  16 years  he operated  upon and studied the morphology of  several  such 
tumours and published a comprehensive review of his work in 1847.
Francesco Durante of Sicily, Italy, was the first surgeon to successfully resect a cranial 
base meningioma.
But the most celebrated work on meningiomas is by Sir Harvey Cushing co – written by Louise 
Eisenhardt  in  1938 titled  “Meningiomas :  Their  classification,  regional  behaviour,  life  history and 
surgical  end  results”.  This  works  gives  incredible  details  and  morphological  descripotions  of 
meningiomas.
Various authours over the years have attempted to classify meningiomas. It was understood that 
most of these tumours followed a benign course and that morbidity and mortality relating to them stem 
from unusual locations and limitations to surgical resectablity.
Cushing5 identified 20 subtypes that included non meningothelial mesenchymal tumours too. 
Further refinement down the year divided meningiomas in to benign, atypical and malignant variants.
The 1993 WHO classification28 recognizes two broad categories of meningeal neoplasms :
1. Meningiomas arising from meningothelial (arachnoidal cap) cells
2. Tumours arising from mesenchymal non meningothelial cells which are classified as soft 
tissue tumours.
Kustanikul  and  Brown42 attributed  the  histological  diversity  of  meningiomas  to  the 
pluripotential nature of mesenchymal stem cells arising from the neural crest.
AIMS AND OBJECTIVES 
1. To study the incidence of intracranial and spinal meningiomas during the five and a half year 
period  from January  2001  to  August  2006  at  the  Institute  of  Neurology  Madras  Medical 
College.
2. To study the distribution of the various sub types of meningiomas with regard to age, sex and 
site.
3. Histopathological  categorization  of  meningiomas  and  grading  them as  per  the  WHO 2000 
classification of Central nervous system tumours.
4. To correlate the histopathological findings with clinical and radiological findings where ever 
possible.
REVIEW OF LITERATURE 
The pachymeninges or duramater and the leptomeninges – the arachnoid membrane and pia 
mater  are  generally  regarded  to  be  mesodermal  in  origin.  The  leptomeninges  have  a  common 
phylogenetic history, develop embryologically in continuity and preserve this intimate relationship in 
their final differentiation and hence are regarded together as “pia – arachnoid”48.
The meninges are composed chiefly of collagen, elastin and reticulin fibres covered by flat cells 
considered t be mesothelial. The fine arachnoidal trabeculae that traverse the sub – arachnoid space are 
covered by these mesothelial cells too. These cells have pale cytoplasm with thin long cytoplasmic 
processes and form several layers.
The cell  of  origin of meningiomas has long been a  matter  of hot  debate.  Endothelial  cells, 
fibroblasts,  primitive  mesenchymal  stem cells  and  arachnoidal  cap  cells  were considered  potential 
candidates at various points of time. This led to the designation of “meningioma” being extended to 
diverse neoplasms that shared only the tendency to arise within the histogenetically complex tissues of 
the leptomeninges or the duramater.  Thus dissimilar entitites  like meningeal hemangiopericytomas, 
hemangioblastomas, solitary fibrous tumours and other meningeal sarcomas were once yoked under the 
term “meningioma”44.
The combination of electron microscopy and immunhistochemistry with in vitro methodology 
of cell lines derived form normal leptomeninges and meningiomas has supported the hypothesis that 
meningiomas are derived from arachnoidal cap cells. These are specialised elements that populate the 
arachnoid membranes and cap the arachnoid villi associated with intra-dural venous sinuses and their 
tributaries48.
CLASSIFICATION OF MENINGIOMAS 
Meningiomas present a bewildering variety of histological patterns.
A classical study by Cushing and Eisenhardt5 demonstrated nine main types and twenty sub 
types.
Later  a  working  classification  identified  only  four  main  types:  syncytial,  fibroblastic, 
transitional and angioblastic.
Uncertainities regarding the histogeneis of the angioblastic types complicated this classification. 
The identification of other variants like papillary and rhabadoid types with less favourable prognosis 
necessitated the formulation of a new classification39.
In 1993, a new WHO classification was formulated which identified 11 sub-types in addition to 
papillary, atypical and anaplastic meningiomas. 
The latest classification has been the WHO 2000 classification28, given below28.
GRADE I
Meningothelial
Fibrous
Transitional
Psammomatous
Angiomatous
Microcystic
Secretory
Metaplastic
Lymphoplasmacytic
GRADE II
Atypical
Clear Cell
Chordoid
GRADE III
Anaplastic / Malignant 
Papillary
Rhabdoid
EPIDEMIOLOGY :-
Literature states that the frequency of meningioma is 20% of all intra cranial neoplasms in men 
and 38% in women. Countries like Africa have a higher frequency at 30%9 in men.
In India meningiomas are the second largest category of brain tumours after gliomas.
A two year report of the population based cancer registries (1999-2000) by the Indian council of 
Medical Research states that in Chennai central nervous system tumours comprise 3.71% of the total 
tumours reported in males and 1.87% of those in females35.
As many meningiomas are asymptomatic, autopsy study material show a higher incidence of 
meningiomas.
 AGE – SPECIFIC INCIDENCE RATES 
Increasing trends are seen with increasing age. From an incidence rate of 0.12 in the age range 
of 0-19 year the rate increases to 18.86 after the age of 80 years.
The ICMR study35 has shown the percentage of brain tumours by the 5 year age group to be 
3.33% in males and 1.94% in females35.
Incomplete reporting, inadequate follow up studies and potential selection biases have limited 
the estimates of mortality associated with meningiomas in the West and more so in India.
However overall survival rates are :
2 year survival rate : 81%
5 year survival rate  : 69%
Population based survival studies from the 1990’s in the United States have put the 5 year 
survival rate as ranging from 73% to 94%2.
Table 1
AGE SPECIFIC INCIDENCE RATES
Claus et al8
Age 0 – 19 20 – 34 35 – 44 45 – 54 55 – 64 65 – 74 75 – 84 85+
Rate 0.12 0.74 2.62 4.89 7.89 12.79 17.04 18.86
SEX SPECIFIC INCIDENCE RATES   
There is a pronounced female predominance, particularly with reference to the benign category 
of meningiomas24.
MALE TO FEMALE RATIO 
1 : 1.4 to 1: 2.8
Hormone receptor status appears to be the main reason behind this females predominance. But 
the incidence in childhood remain equal among boys and girls with some studies demonstrating a male 
predominance.
Furthermore,  men are  found to  have  a  higher  incidence  of  the  more  ominous  atypical  and 
anaplastic meningiomas.
RACE :  
Meningiomas are more prevalent in Africa than the West., even there African – Americans form 
a major part of the population diagnosed with meningiomas9.
RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF MENINGIOMAS
The two factors for which the strongest evidence exists  with respect to an association with 
meningioma risk are
1) Exposure to ionizing radiation
2) Hormones
Ionizing Radiation 
  Ionizing radiation increase the risk of intra cranial tumours particularly meningiomas, probably 
by damaging the DNA9.
Mann  et  al  reported  the  first  case  of  radiation  induced  meningioma  following  high  dose 
radiation to the orbit in a four year old child following the resection of an optic nerve glioma.
Commonly meningiomas occur after radiation therapy for pituitary adenoma, glial tumours and 
scalp abnormalities like tinea capitis.
Dental radiographs are another important causative factors of meningiomas. A population based 
case  control  study  by  the  University  of  Washington  Seattle  shows  that  dental  X-rays  do  cause 
meningiomas26.
Meningiomas also occur following high dose radiation therapy for other primary intra cranial 
tumours.
Factors  like  tissue  vulnerability,  radiation  type  and dose,  underlying  disease and additional 
chemotherapy  may  influence  tumorigenesis  of  meningiomas  after  another  primary  intracranial 
neoplasm has been irradiated.
Dore et al26 found that the majority of secondary tumours were within the margin region of the 
treatment volume, when the volume received was less than 6 gy.
The average time of tumour induction is twenty one years after high dose therapy compared 
with thirty five years following low dose therapy.
A recent case control study of 200 meningioma reported on odds ratio of 2.06 (C.I :  95%) 
showing a strong association with radiation and meningiomas.
Hormones       
Several factors point to the association of meningioma and hormones.
1) Increased incidence of the disease in women compared to men
2) The presence of progesterone, rarely estrogen and sometimes androgen receptors in meningiomas.
3) The association of breast cancer and meningiomas13.
4) Change in the size of meningiomas during the luteal phase of the menstrual cycle and pregnancy. 
Endogenous Hormones :-
Exposure to hormones may be exogenous or endogenous. A population based study of brain 
tumours from the late 1980s found that women with natural or surgical menopause (RR 0.59 – 0.12) 
had a reduced risk of meningiomas9.
Similarly in the Nurses Health Study48 the relative risk for meningiomas was less for candidates 
with late menopause. This study has also observed an increased risk for parous women compared with 
nor parous women. But other studies have found pregnancy protective.
Exogenous Hormones :-   
Only recently have researchers started addressing the issue of exogenous hormones in the form 
of hormone replacement therapy and oral contraceptives. In a case control study inserted within the 
Nurses Cohort study9 that included 125 meningiomas an overall  positive association with hormone 
replacement therapy was found. Another case control study from three Chicago hospitals between 1987 
and 1992 reports a protective effect for contraceptives9.
A retrospective cohort study using the Mayo Clinic Jacksonville patients database confirms the 
positive association of HRT and meningiomas9.
These slightly contradictory findings emphasize the need for larger well controlled population 
based studies.
Head Trauma :
Since the time of Harvey Cushing, trauma has been suggested as a risk factor for meningiomas. 
Several small case studies from the 1980’s report a positive association with meningioma.
In a cohort study of 228,055 Danish residents hospitalized for head trauma between 1978-1992 
the standardized incidence ratio was 1.2 (95% CI) 9. 
Cell Phone Use :
Exposure to the electromagnetic fields from cell phone use and the subsequent meningioma 
risk, though of great public interest has not been substantiated. This is partly because cell phone use 
began a relatively short while ago and the few conducted studies were of small sample size. 
Breast Cancer Association With Meningioma
Common risk factors and shared genetic predisposition may be the reason why meningiomas 
are  seen  commonly  associated  with  breast  cancer.  Studies  have  shown  that  BRCA1  or  BRCA2 
mutations are not found in sporadic meningiomas.
The relative risk for the association between breast cancer and meningioma observed across 
currently existing studies range between 1.5 and 2.0 with the majority being statistically significant.
Allergy :   
Contrary to the positive association between glial tumours and allergy, no such association has 
been found for meningiomas. Few large population based studies have proven this non – association.
 Viruses :
Though  several  viruses  have  been  implicated,  papovavirus  DNA  has  been  found  in 
meningiomas. But a definite role for viruses is yet to be proven9.
CYTOGENETICS :
Consistent  cytogenetic  abnormalities  are  found  between  60  and  100%  of  meningiomas, 
depending on the various epidemiological factors and the laboratory technique used.
Both chromosomal loss and structural abnormalities are found. The most frequent chromosomal 
abnormality is simple monosomy of chromosome 22 in about 70-80% of cases. Less often a deletion of 
Ch. 22q occurs instead of simple monosomy. Of the other chromosomes Ch 14, is frequently involved 
in non-random loss or structural rearrangements2. Chromosomes 1, 7, 14 and Y and to a lesser degree 
18, 19 and 20 are also noted.
A recent cytogenetic study has raised the possibility of chordoid meningiomas being associated 
with a characteristic translocation of chromosome arms 1p and 3p : t(1 : 3) (p12 – 13, q11).
In the early stages of development meningiomas are likely to have a normal karyotype or a 
simple monosomy. As the neoplasm progresses the karyotype becomes increasingly hypodiploid and 
later structural rearrangements may occur13.
The  increasing  grades  of  the  meningiomas  are  associated  with  chromosomal  changes  of 
increasing complexity. 
In a study of 765 meningiomas the grade I meningiomas were found largely to have a normal 
karyotype, or monosomy 22. Grade II meningiomas were found to have both numerical and structural 
abnormalities. Fibroblastic meningiomas were found to have telomeric associations9.
Meningiomas of the convexity were often grade II  or III  with loss of chromosome 22 and 
complex karyotypes.
The consistent losses of 22q followed by 1p, 1O and 14q strongly suggests the presence of 
meningioma tumour suppressor genes on these chromosomal arms. Analysis of polymorphic loci in 
DNA has supported the hypothesis that the loss of a tumour suppressor gene from the long arm of 
chromosome 22 to be the initiating genetic event in the pathogenesis of meningiomas34. 
NF – 2 gene in meningiomas :
         Mutations in the NF2 gene are found in upto 60% of benign meningiomas and are probably 
inactivating mutations. Most of there mutations are small insertions or deletions or nonsense mutations.
Among benign meningiomas,  the frequency of  NF2 mutations varies.  Both fibroblastic  and 
transitional variant carry NF2 gene mutations in 70-80% of cases while meningiothelial meningiomas 
to so only in 25% of cases.
Chromosome 22q may harbour a second meningioma gene. β - adaptive gene, found in a region 
of 22q, has been found to be disrupted by translocations in several meningiomas.
Atypical  and  malignant  meningiomas  consistently show losses  in  1P,  10  and 14q.  Loss  of 
chromosome 10 is associated with morphological signs of malignancy2.
SPECIALISED CATEGORIES OF MENINGIOMAS
Radiation Induced Meningiomas
Rubenstein et al34 defined radiation induced meningiomas as a separate nosological entity due to 
distinct clinico pathological featuers with regard to their presenting symptoms, multiplicity, recurrence 
rate and histopathology.
They characteristically occur in younger populations who have received a high dose of ionizing 
radiation. This suggests that the effect of radiation on the younger vulnerable meninges is more.
Clinically the hallmarks of radiation induced meningioma are alopecia and an atrophic scalp 
that overlies the meningioma.
The average time to tumours induction is 21 years for high doses and 35 years for low doses 
indicating that the chromosomal injury caused by higher doses elicit more rapid loss of cell control 
mechanisms and earlier expression of the neoplastic phenotype34.
The  frequency  of  atypical  meningiomas  is  more  among  radiation  induced  cases.  Similarly 
multiplicity is  far  more common. But surprisingly proliferation indicies like chromo deoxy uridine 
labeling indices, PCNA and Ki – 67 labelling indices show a slow growth potential2.
Cohan  et  al  have  laid  down  the  following  criteria  to  label  a  meningioma  as  “radiation  – 
induced”
1. The tumour must occur within the field of irradiation.
2. The tumour must differ from any pre existing neoplasm.
3. It must occur after a reasonable interval, sufficient to demonstrate that the neoplasm did not 
exist prior to radiation.
4. Significantly higher incidence in the irradiated groups compared to the control groups.
Studies have long stressed the need for life long clinical and radiological surveillance of cranially 
irradiated patients.
ATYPICAL AND ANAPLASTIC MENINGIOMAS :
   Various sources put the incidence of meningiomas at 13-26% of all intracranial tumours. A 
minority of these tumours possess aggressive qualities. Atypical meningiomas constitute about 4.7 – 
7.2% of all meningiomas while anaplastic meningiomas comprise 1-2.8%2.
2% of  all  benign  meningiomas  transform  into  more  malignant  forms,  while  28.5%  of  all 
recurrent benign meningiomas turn out to be atypical or anaplastic30.
They are more common in men than women.
Additional genetic mutations are responsible for atypical and anaplastic features.
Atypical meningiomas carry mutations of Ch 22q, a gain of 1q, 9q, 15q and 17q or lss of 1p, 6q, 
10q, 14q or 18q.
Anaplastic meningiomas are fund to have further mutations like amplification of 17q and loss of 
9p.
CLINICAL PRESENTATION OF MENINGIOMAS :
Meningiomas produce symptoms by several mechanisms like irritation of the underlying cortex, 
compression  of  the  brain  or  nerves,  hyperostosis  of  the  overlying  bone,  soft  tissue  invasion  and 
vascular compromise10. Hyperostosis does not always occur due to direct bony permeation but may be 
a  consequence  of  increased  sub-periosteal  bone  formation  stimulated  by  impaired  blood  supply. 
Meningiomas contain high levels of alkaline phosphatase that is known to possess indirect ossifying 
properties.
Characteristic symptoms are produced by site specific meningiomas.
Para Sagittal : Monoparesis of contralateral leg
Sub-frontal : Change in mentation
Olfactory groove : Foster – Kennedy  syndrome
Cavernous sinus : Multiple cranial nerve deficits
Occipital lobe : Contralateral hemianopia
Cerebello-pontine angle : Decreased hearing
Spinal cord : Back  pain,  Brown  –  Sequard  syndrome, 
paraparesis.
QUALITY OF LIFE : 
Though  classified  clinically  and  histopathologically  as  benign,  the  clinical  effects  of 
meningiomas can be devastating. Upto 30% of patients operated for meningiomas cannot read, write, 
drive or even think at the same level as before their diagnosis.
DIAGNOSIS OF MENINGIOMA 
No specific laboratory test are available for screening meningiomas. Levels of linolineic acid 
may raised in the serum29. Imaging studies are the mainstay of diagnosis.
X – RAYS :  
Meningiomas may exhibit the following features on x- rays
- Hyperostosis of the overlying bone
- Increased vascular markings
- Intra-cranial calcifications
CT SCANS :
Dural based lesions that are iso-attenuating to hyperattenuating. They enhance homogenously 
and intensely after the injection of iodiated contrast material. Perilesional edema is usually marked. The 
underlying brain may be compressed. Multiple lesions are difficult to differentiate from metastasis.
MRI – MAGNETIC RESONANCE IMAGING : 
On T1 and T2 weighted MRI’s the tumours have variable signal intensity. Enhanced MRI’s are 
imperative for a diagnosis of meningioma. Meningiomas enhance intensely and homogenously after 
injection of gadolinium gadopentate. Peri lesional edema may be more apparent on MRI than CT scans. 
An enhancing tail involving the duramater may be apparent on MRI.
ANGIOGRAPHY :
Angiography features of meningiomas demonstrate the following :
 Vascular supply from the external circulation
 So called “ mother in law blush” a vascular blush that comes on early and leaves late.
 Sun burst or radial appearance of the feeding arteries.
PROGNOSTIC FACTORS IN MENINGIOMAS  
The 2000 WHO classification of meningiomas provides a grading system for menigiomas based 
on histological criteria that has a pronounced impact on prognosis.
Over the years several authours like Rubenstein, Tallkalnin and Mahmood have attempted to 
classify and grade meningiomas but had inconsistent results.
Two well structured studes by Perry et al from the Mayo clinics have a simply worked out and 
very reproducible grading system2.
The Mayo Clinic Grading Scheme Pathological Criteria 
Atypical Meningioma
≥ 4 Mitosis / 10hpf
Or at least three of the following features
Sheeting 
Macronucleoli
Small cell formation 
Hyper cellularity (> 53 nuclei/hpf)  
Brain invasion
Anaplastic meningiomas
≥ 20 mitosis / 10 hpf
or
Focal or diffuse loss of meningothelial differentiation resulting in a carcinoma, sarcoma or melanoma 
like appearance.
HORMONE RECEPTOR STATUS  
Some hormones and their receptors have been studied extensively in meningomas due to the 
increased growth rates of meningiomas with raised sese hormone levels.
Estrogen Receptors :
Donnell et al1 first described the presence of estrogen receptors in four out of six meningiomas. 
They are  fund at  in  a  much lower percentage  of  cases  when compared to  progesterone receptors. 
Ligand binding and enzyme immunoassay does not reveal estrogen receptors but hand shift assays have 
found an estrogen like protein. Estrogen receptor related small heat shoed protein (HSP – 27) has also 
been demonstrated.
Data  from the  Brigham and  Women’s  Hospital1 has  shown variations  among  the  estrogen 
receptors iso-forms. 68% of cases express receptors alpha mRNA and 32% express beta mRNA. Both 
types are capable of binding estrogen and activating genes, but elicit different responses in different 
organs. A more detailed sub-typing of estrogen receptors may explain why anti-estrogen drugs like 
tamoxifen has yielded inconclusive results.
Progesterone  Receptors  
Progesterone receptors are found in 40-100% of meningiomas.
Hsu et al47 have shown that benign menigiomas were more likely to be PR positive.
PR status is immensely related to the mitotic index and grade and therefore associated with a 
between prognosis.
Jay et al have shown that hormonal manipulation may modify the growth in some tumours.
In in vitro growth of meningioma cells, Koper et al suggested that the presence of progesterone 
in  the  culture  medium increases  the  sensitivity  of  the  meningioma cells  to  mitogenic  stimuli  like 
epidermal  growth  factor.  Mifepristone  a  progesterone  receptor  blocking  agent  can  counteract  the 
effects of progesterone.
Studies  by  Grunberg  et  al  have  shown  that  mifepristone  may  play  a  role  in  tumour  size 
reduction particularly in benign meningiomas.
High progesterone receptors expression are found in the following groups :
1. Male patients in the age group above 50 years.
2. Grade I meningiothelial meningiomas when compared to fibrous or transitional variants.
3. Meningiomas with a low MIB – 1
4. Atypical and anaplastic meningiomas show low progesterone receptor indices.
A recent paper by the American Cancer Society further studied the status f progesterone receptors 
and  MIB –  1  status  with  relation  to  age.  They have  concluded  that  either  index  has  no  definite 
relationship with age and that atypical a anaplastic variants could occur in old age.
MIB – 1 LABELLING INDICES :
Predicting the biological behaviors and propensity for recurrence has roved to be notoriously 
difficult in meningiomas. various proliferation indices like MIB – 1 labelling indices have been tried.
MIB – 1 is a monoclonal antibody that detects Ki 67 antigen, a non-histone protein expressed 
only in the proliferative phase of the cell cycle i.e., during G1, S, G2 and (Mitotic) M phase. It was 
earlier considered to be a reliable marker for higher grade tumours. But larger scale studies have shown 
that a high MIB-1 index need not predict recurrence.
Other factors like tumour location, grade of excision of surgery and tumour histology are more 
predictive indications of recurrence.
SURGICAL GRADE OF EXCISION  
Simpson’s  grading  schemes29 have  categorized  the  extend  of  surgical  resection  for 
meningiomas.
Table 2
Grade I Total  Macroscopic  Resection  With  Dural  Attachment  /  Bone 
Involved Sinus 
Grade II Total resection and diathermy of attachment 
Grade III Total macroscopic resection of tumour only
Grade I resection had the best rate of recurrence when compared to grade III, emphasizing the 
need for complete resection.
SITE OF OCCURRENCE OF THE MENINGIOMAS 
The highest rate of recurrence has been documented for olfactory groome meningiomas and 
basal meningiomas at 41.7% followed by cerebellopontine angle tumours and posterior fossa tumours. 
Recurrences are the least among convexity meningiomas.
MOLECULAR BIOLOGY OF MENINGIOMAS 
Oncogene  expression  analysis  has  revealed  a  host  of  growth  factor  and  their  receptors  in 
meningiomas.
Platelet derived growth factors (PDGF – A, PDGF – B and PDGF - β receptor) are found to be 
increased and they further raise C – fos levels. PDGF – A and PDGF - β receptors are involved in the 
growth control of meningiomas through autocrine and paracrine mechanisms.
In in vitro studies have revealed other powerful mitogenic agent like epidermal growth factor in 
meningiomas.  Somatostatin  receptors are present in all  those tumours that  contain EGF leading to 
interaction of the two.
Meningiomas also expressed insulin like growth factor 1 and 2 in excess of the amounts found 
in normal brain and meninges.
Suramin, a polyanionic compound that interferes with growth factor to cell binding has been 
shown to inhibit meningioma growth and holds therapeutic promise.
bFGF  (basic  fibroblastic  growth  factor)  levels  are  increased  and  function  as  mitogens, 
angiogenic agents and differentiators. Intracellular calcium levels appear to play a key role in their 
voltage dependent signal transduction methods.
VEGF (Vascular endothelial  growth factor)  is  a potent angiogenic agent that  also acts  as a 
vascular  permeability  molecule.  The  distinctive  peri-tumoural  edema  is  attributed  to  the  effect  of 
VEGF.
Endothelin, a potent vasoconstrictor also acts as a growth promoting agent in meningiomas.
Down stream mediators of cellular  proliferation like the multiple JAK/STAT molecules are 
particularly elevated in transitional meningiomas.
All  these  growth  factors  are  being  investigated  as  potential  targets  of  molecular  targeted 
therapy.    
MATERIALS AND METHODS
This is a single Institution based study of all the meningiomas received at the Department of 
Neuropathology, Madras Medical College, during the period from January 2001 to August 2006.
The total number of central nervous system tumours received during this period were 1946, of 
which 342 were meningiomas.
All these 342 cases were diagnosed pre – operatively as meningiomas by imaging studies, either 
CT scans or MRI.
Medical records of all the patients were reviewed and supplemental clinical information was 
obtained from the treating physician where ever necessary.
The recorded clinical data include the patients age, sex, history of any significant co-morbidity, 
imaging findings, location of the tumour, date of surgery, extent of surgical resection and additional 
therapy given if any.
All  the  specimens  were  received  and  fixed  in  10% buffered  formalin  and  were  manually 
processed.
Gross features like the overall size, shape,  colour,  consistency,  cystic and necrotic changes, 
attached duramater and bone were evaluated. Where ever possible the specimens were bisected along 
the longitudinal diameter and a minimum of four bits each measuring 3 – 5 mm in thickness were 
taken.  After  manual  processing  sections  of  3  –  5  micron  thickness  were  cut  and  stained  with 
hematoxylin and eosin. In some cases additional special stains like periodic acid Schiff and Verhoeff’s 
Van Gieson were performed.
The meningiomas thus diagnosed were subtyped into various histological types.
Grading of the meningiomas was done as per the WHO 2000 classification of Central nervous 
system tumours into grade I, II and III.
The distribution of these various histological types of meningiomas with reference to age, sex 
and site of occurrence were analysed and compared with data from other studies.
Further,  recent  literature  regarding the epidemiology,  clinical  presentation,  etiopathogenesis, 
grading and other prognostic factors were reviewed.
     
    
PROCEDURE FOR HEMATOXYLIN AND EOSIN STAINING 
1. Dewax the section, dehydrate through graded alcohols and bring sections to water.
2. Remove fixation pigments if necessary, stain in haematoxylin for 5 minutes.
3. Wash well in running tap water. 
4. Differentiate in 1% acid alcohol  for 2- 4 seconds. 
5. Wash well in running tap water until sections are blue again for 15 – 20 minutes.
6. Stain in eosin for one minute 
7. Wash in water for 5 minutes
8. Dry the sections, clear in xylene, mount with DPX, and label the slide
OBSERVATION AND DISCUSSION
At the Department of Neuropathology, Madras Medical College, a total of 2702 specimens were 
received for histopathological examination during the period extending from January 2001 to August 
2006.
Out  of  these  2702  specimens  there  were  1946  central  nervous  system  neoplasms,  which 
encompassed  a  wide  range  of  lesions  including  gliomas,  meningiomas,  oligodendrogliomas, 
schwannomas, etc.,
Among them gliomas formed the largest category with a total of 623 cases. 
Our study showed that the total number of meningiomas received during this five year period 
was 342. They formed the second largest category after gliomas. Other tumour of the meninges too 
were reported during this period,  which include 9 haemangiopericytomas.  These tumours were not 
taken up for this study as they have been excluded form the category of meningiomas by the new WHO 
2000 classification.
As per the WHO 2000 classification there were 320 grade I tumours, 11 grade II tumours and 
11 grade II tumours.
AGE SPECIFIC INCIDENCE :  
In our study there was a wide age range with the youngest candidate being 5 years of age and 
the oldest 78 years of age.
The peak incidence was found in the fifth decade with 104 cases contributing to 30.40% of the 
cases. The least incidence was recorded in the eight decade with only a single 78 year old man in the 
entire 5 year study period.
The number of cases in the first decade too was low with 10 cases in 5  years.
The frequency of meningiomas at our institute as per our study is 17.47% (342 meningiomas 
out of 1946 CNS neoplasms).
This  finding is  comparable  with  statistics  quoted  in  literature9 that  places  the  frequency of 
meningiomas at 20%.
According to Indian literature meningiomas account for the second largest group after gliomas. 
The statistics from our study are comparable with that of a similar hospital based study of meningiomas 
conducted at Bombay Hospital by A.B. Shah et al42. They too found that meningiomas were the second 
largest group with 267 meningiomas out of a total of 1321 CNS space occupying lesions.
INCIDENCE OF MENINGIOMAS OVER THE STUDY PERIOD
The incidence of meningiomas at our Institute over these five and half years has not been 
constant but subject to fluctuations.
Table 3
DISTRIBUTION OF CASES OVER A FIVE AND HALF YEAR PERIOD  
Year No. of cases
2001 58
2002 43
2003 54
2004 69
2005 48
2006 (upto August) 65
The highest incidence has been the year 2006 with 65 cases being reported over a period of 
eight months. The average number of meningiomas reported per year is about 62 at our Institute    
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Table No. 4
AGE DISTRIBUTION OF MENINGIOMAS
Age group (Years)
No. of cases
n = 342
Percentage
0 – 10 10 2.92%
11 – 20 18 5.26%
21 – 30 48 14.03%
31 – 40 91 26.60%
41 – 50 104 30.40%
51 – 60 47 13.74%
2001 2002 2003 2004 2005 2006 
(upto August)
61 – 70 23 6.72%
71 – 80 1 0.29%
 Our study showed a gradually increasing age specific  incidence rate from the first  decade 
onwards. This peaked at the fifth decade with 104 cases forming 30.40%.
The incidence  rate  thereafter  tapered  off  till  the  eight  decade  which  showed only a  single 
reported case.
Literature  from the  west9 shows  that  the  age  specific  incidence  rate  rises  from childhood 
onwards and reaches a peak in the 8th decade. The findings in our study and in the study at Bombay 
Hospital do not corroborate with the same. A.B. Shah et al42 too showed a peak incidence in the fifth 
decade with 26% of their cases falling in this age group.
The reasons why in India statistics tend to remain low in the elderly age groups are probably 
poor availability of health services to the aged when compared to their western counterparts.
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Most of the patients in our hospital hail from poor socio – economic groups, particularly from 
rural  areas.  Several  elderly patients  have associated co – morbid conditions like diabetes mellitus, 
hypertension and ischemic heart disease, which increase the risk for anaesthesia. Further many elderly 
patients and their families show a general reluctance to undergo a major neurosurgical procedures with 
all its attendant risks. All these factors along with a general lack of awareness of the condition may be 
the reason for the low incidence of meningiomas in the older age groups in India.
Meningioma Age Distribution  
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SEX – SPECIFIC INCIDENCE RATES
In our study among a total number of 342 meningiomas, there were 212 female patients and 130 
male patients.  The sex specific  incidence rate  for women was thus 61.98% and that  for men was 
38.01%.
This overall female predominance was not seen in the pediatric age group. In the first decade, 
out of a total of 10 cases there was a pronounced male predominance with 9 males and one female. 
There findings correlate with other studies on childhood meningiomas as in the one by E.J. Rushing et 
al10. Of 87 child hood meningiomas studied by them, there were 52 males and 35 females.
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A study by Claus et al on the epidemiology of meningiomas show that women have a higher 
incidence of meningiomas9. The overall incidence rate is reported to be 38% for women compared to 
20% in men.
Our study showed the largest number of female patients in the fourth decade with a total of 65 
women.  This  predominance  of  women  can  be  partly  explained  by the  fact  that  meningiomas  are 
hormone dependent. Progesterone specially acts as a potent growth factor1. Our study had two women 
who were pregnant  when diagnosed with meningioma.  Surgery was performed in  the post partum 
period in both these women. Both women experienced an increase in the size of the tumour during 
pregnancy.  
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CLINICAL FEATURES :-
Our study revealed that the symptoms and signs among various patients varied according to the 
site of the tumour.
The most common presenting symptoms were headache associated with vomiting or nausea. 
52%  of  all  the  cases  had  these  symptoms.  New  onset  seizures  were  the  second  most  common 
symptoms accounting for 20% of all the cases. Children in particular presented with seizures more 
often than any other symptoms.
Other  commonly  observed  symptoms  were  urinary  incontinence,  memory  disturbances, 
behavioural abnormalities twitching of the face, derivation of mouth, rarely hemiparesis or hemiplegia. 
These symptoms were observed mostly in supra – tentorial meningiomas. Some patients experienced 
drowsiness or were even admitted in a comatose condition.
Orbital meningiomas presented with progressive proptosis, reduction of visual acuity and rarely 
with total blindness.
Spinal  cord  meningiomas  presented  with  back  pain  in  80%  of  the  cases.  Some  patients 
presented with paraparesis, numbness in the lower limbs and difficulty in getting up or walking. Two 
patients with spinal cord lesions in the 6th decade presented with pathological features.
Cerebellopontine  angle  meningiomas  manifested  with  ataxia,  nystagmus,  or  reduction  in 
hearing.
Three patients presented primarily with bony swellings of the scalp which later were diagnosed 
as underlying meningiomas with osseous involvement.
Exacerbation of symptoms during the course of pregnancy were noted in both women who were 
diagnosed during their pregnancy.
In our study four patients had a history of previous head trauma. Three male patients developed 
meningiomas at the site of head injury following road traffic accidents after a mean period of five 
years. One female patient reportedly developed a meningiomas 3 year after a fall from a height.
There were two patients who had a history of cranial surgery but no case of cranial irradiation 
was noted in our study.
Table 5 :- CLINICAL FEATURES IN MENINGIOMAS
Signs Frequency (n =342)
Headache, Vomiting / Nausea 52%
Seizures 20%
Back ache 12%
Paraparesis / paraplegia 4%
Ataxia, deafness 3%
Reduction of vision 1%
Others 8%
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CO – MORBID CONDITIONS
Several elderly patients in our study had co – existing morbid conditions like diabetes mellitus, 
ischemic heart disease and hypertension.
Some patients had so – existent tumours while some were treated earlier for other malignancies. 
One 12 year old boy had a history of a schwannoma operated about a year before diagnosis of a spinal 
cord meningioma.
A 37 year old female had a co – existent neurofibroma, with a meningiothelial meningioma. 
Both were operated upon in two different surgeries.
Two women, both in the fifth decade were known cases of carcinoma cervix: one stage III, the 
other stage II. Both had undergone surgery and radiotherapy on an average of five years before being 
diagnosed with meningiomas.
A forty year old male with a left sided sphenoid wing angiomatous meningioma had Foster – 
Kennedy syndrome.
Literature  states  that  meningiomas  occur  commonly in  patient  with  neurofibromatosis  type 
(NF2), Gorlins’ syndrome and Down’s syndrome10. Several co – existent tumours have been reported 
along with meningiomas like medulloblastomas,  primitive neuroectodermal tumours, schwannomas, 
astrocytomas, retinoblastomas and rarely cases of leukemia.
The three cases  of  lympho – plasmacytic  meningiomas reported in  our  study did not  have 
monoclonal gammopathy or endocrine abnormalities but two of then had anaemia. 
Similarly chordoid meningiomas are closely associated with Castleman’s disease but the single 
reported case in our study did not4.
The association of meningiomas with breast carcinomas too is well known. We did not see any 
case with a history of breast carcinoma1. Follow up studies were inadequate as most cases were lost to 
follow up.  
IMAGING STUDIES   
Out of the total 342 meningiomas in our study imaging study details were available for 237 
cases. Of these computerized tomography (CT) scans were done pre – operatively in 181 cases while 
magnetic resonance imaging (MRI) scans were done in 56 cases.
Analysis  of the results  of computerized tomographic imaging of meningiomas revealed that 
hyperdense  lesions  numbered  96  out  of  the  181 cases  done.  Most  of  these  cases  were  fibrous  or 
meningiothelial  meningiomas.  No site or age predilection was noted.  Isodense lesion on CT scans 
numbered 46 while hypodense lesions were 20 in number. Mixed dense lesions were 19 which included 
two papillary, one rhabdoid and four atypical meningiomas.
Most of the lesions showed extensive perilesional edema.
In  those  cases  where  contrast  enhanced  CT  scans  were  done,  brilliant  enhancement  with 
contrast was noted. Intra tumoural calcification was picked up, in many psammomatous meningiomas.
Magnetic resonance imaging showed that 35 cases were hypointense on T1 weighted MRI and 
hyperdense on T2 weighted MRI, while 21 cases were iso intense on T1 weighted MRI hyperdense 
images on T2 weighted MRI which 21 cases were iso intense on T1 weighted MRI hyperdense images 
on T2 weighted MRI.
Perilesional edema was appreciated better on MRI scans than CT scan studies.
Table No.6 :        CT SCAN DATA  DISTRIBUTION
Image findings
No. of cases
n = 181
Percentage
Hyperdense lesions 96 53.03%
Isodense Lesions 46 25.41%
Hypodense Lesions 20 11.01%
Mixed Dense Lesions 19 10.49%
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SITE SPECIFIC INCIDENCE OF MENINGIOMA 
Of the total number of 342 meningiomas, the vast majority of them were intracranial in location 
numbering 303. The remaining 39 meningiomas were intraspinal in location.
Among the intracranial tumours most were supratentorial and dural based.
The most common location for the intra cranial tumours were the frontal lobes followed by the 
parietal lobes.
The distribution of the studied meningiomas among various sites is given below.
Table 7 
Location of the tumour
No. of cases
n = 342
Percentage
Frontal 63 18.42%
Parietal 62 18.12%
Para Sagittal 13 3.80%
CP Angle 20 5.84%
Sphenoid wing 23 6.72%
Posterior Cranial Fossa 14 4.09%
Falx 24 7.01%
Temporal 20 5.84%
Suprasellar 8 2.33%
Intraventricular 10 2.92%
Orbital 6 1.75%
Clival 1 0.29%
Basal 2 0.58%
Spinal Cord 39 11.40%
Miscellaneous 47 13.74%
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Table 8 
COMPARISON OF ANATOMIC LOCATIONS OF INTRACRANIAL MENINGIOMAS
Location of the tumour
PRESENT STUDY A.B. SHAH et al
No. of 
cases
n = 342
Percentage
No. of 
cases
n = 247 Percentage
Frontal 63 18.42% 69 28%
Parietal 62 18.12% 33 13%
Middle cranial fossa 59 17.25% 36 15%
CP Angle 20 5.84% 24 9%
Suprasellar 8 2.33% 17 6%
Temporal 20 5.84% 16 6%
Falx 24 7.01% 12 5%
Posterior Cranial Fossa 14 4.09% 16 6%
Miscellaneous 90 26.31% 24 9%
These figures corroborate with other studies. The epidemiological study by A.B. Shah et al42 
from Bombay Hospital show similar statistics.
Certain site specific meningiomas carry prognostic and surgical implications. 
INTRAVENTRICULAR MENINGIOMAS
Intraventricular meningiomas are considered rare tumours. The origin of these tumours can be 
traced to embryological invagination of arachnoidal cells into the choroid plexus. Our study revealed 
ten meningiomas located intraventricularly. Bhatoe et al3 reported 12 cases, from the Army Hospital, 
New Delhi. All were slow growing tumours and most of them were angiomatous meningiomas.
Out  of  10  cases,  8  tumours  were located  in  the  lateral  ventricles,  one  tumour  in  the  third 
ventricle and one in the fourth ventricle.  There were six meningothelial  meningiomas,  two fibrous 
meningiomas, one angiomatous meningioma and one papillary meningioma. They were no different 
histologically from dural based examples.
Sphenoid Wing Meningiomas 
Sphenoid  wing  meningiomas  are  considered  challenging  to  the  neurosurgeon  due  to 
involvement of the adjacent bone31.  The site of tumour origin,  and the presence or absence of the 
arachnoidal plane between the tumour and cerebral vessels affect resectability. 
Though  most  are  benign  meningiomas  they  occupy the  parasellar  region  with  its  complex 
anatomical  boundary  zone  between  orbital  and  intracranial  compartments  including  the  cavernous 
sinus, prejudicing radical surgery.
Sphenoid wing meningiomas with osseous involvement are considered a separate entity by most 
neurosurgeons. Grossly these meningiomas may be of two types : a globoid variant and an en plaque 
variant11. The latter form is characterized more by its clinical and radiological appearance rather than 
histology. They are more likely to produce hyperostosis or even show direct infiltration of the sphenoid 
wing.
Hyperostosis due to meningiomas :        
The cause of associated hyperostosis in meningiomas at the sphenoid bone remains a point of 
controversy – specifically regarding whether this represents a secondary change of the bone without 
tumour invasion or a direct infiltration of the bone by the tumour.
The mechanism by which meningiomas accomplish this extensive invasion of bone may be due 
to preceding trauma, vascular disturbances enzymatic reactions, or stimulation. 
Impaired  blood  supply  due  to  tumour  growth  may  induce  increased  sub  periosteal  bone 
formation. The level of alkaline phosphatase which is known to possess indirect ossifying properties is 
found to be three times higher in meningiomas with osseous involvement than those without5.
Pompili  et  al11 studied  and  demonstrated  that  there  is  true  hyperostosis  with  formation  of 
additional bone and that the invasion of bone is not merely a lytic process.
In  spite  of  this  seemingly  aggressive  growth  pattern,  sphenoid  wing  meningiomas  are  not 
different histologically from those occurring at other sites. In our study there were 23 sphenoid wing 
meningiomas.
There were 12 meningothelial meningiomas making up the largest category. There were four 
fibroblastic  meningiomas,  three  angiomatous  meningiomas,  two  transitional  meningiomas,  one 
metaplastic variant and one atypical example.
Table 9 shows the comparison between the study by F.Roser et al and the present study.
DISTRIBUTION OF HISTOLOGICAL TYPES AMONG SPHENOID WING MENINGIOMAS 
   
Histological 
Type 
Study by F.Roser et al
n = 82
Present study
n= 23
Meningiomas No. of cases Percentage No. of cases Percentage
Meningothelial 58 70.73% 12 52.17%
Fibrous 4 4.87% 4 17.39%
Transitional 5 6.09% 2 8.69%
Atypical 5 6.09% 1 4.34%
Others 10 12.19% 4 17.39%
We found a slightly higher incidence of fibrous and angiomatous meningiomas and a lower 
incidence of atypical examples. 
SPINAL CORD MENINGIOMAS
Our  study  showed  extra  cranial  meningiomas  located  only  in  the  spinal  cord.  Other  sites 
reported  in  the  literature  include  lung,  ovary,  soft  tissue  etc.,  but  we did  not  encounter  any such 
examples.
Spinal cord meningiomas occurred across all age groups and occurred in both sexes with equal 
frequency.
The most common site of occurrence was the thoracic spine with a predilection for the 6th – 8th 
thoracic vertebrae.
Of  the  studied  39  spinal  cord  meningiomas,  psammomatous  meningiomas  were  the 
predominant type with 23 cases making up 58.97%. Meningiothelial meningiomas were the second 
most common category with 8 cases.
A  study by  Walter  Reed  Army Medical  Centre,  spinal  cord  meningiomas  demonstrated  a 
predominance of psammomatous types too. Childhood meningiomas presenting in the spinal cord too 
tend to be psammomatous in types.
Table No.10 
HISTOLOGICAL VARIANTS OF SPINAL CORD MENINGIOMAS
Types No. of Cases
n = 39
Percentage
Psammomatous 23 58.97%
Meningiothelial 8 20.51%
Fibrous 4 10.25%
Transitional 3 7.69%
Angiomatous 1 2.56%
MULTIPLICITY IN MENINGIOMAS  
Multiple synchronous tumours were encountered in three patients in our series. A thirty year old 
female  with  recent  onset  seizures  and  loss  of  consciousness  was  diagnosed  to  have  multiple 
meningiomas by MRI scan. They were located in the corpus callosum, (R) parietal lobe, (R) occipital 
lobe and (L) para – sagittal area. All four tumours showed features of meningiothelial meningioma. A 
27 year old male presented with headache and vomiting of short duration. CT scan findings showed 
one  tumour  in  the  (L)  fronto  parietal  area  and  one  in  the  (L)  sphenoid  bone.  Histopathological 
examination  of  the  frontoparietal  mass  showed  a  fibrous  meningiomas  while  the  (L)  sphenoid 
meningiomas turned out to be a psammomatous variant.
An elderly male patient aged 66 years presented with diminution of vision. CT scans showed 
bilateral occipital tumours, that were found to be anatomical distinct from each other during surgery. 
Both tumour were  meningothelial meningiomas.
Multiple meningiomas are usually reported to occur in patient with neurofibromatosis 2 (NF – 
2) 24. Though there are various criteria for the diagnosis of NF – 2, all require either a family history of 
NF – 2 or presence of a vestibular schwannoma. All three of our patients with multiple meningiomas 
had  neither.  Families  with  multiple  meningiomas  have  been  reported  without  chromosomal  22q 
reported without chromosomal 22q deletions and it is hypothesized that this disorder may result from 
alterations in other negative growth regulators important for meningial cell growth and differentiation.
None of our reported patients had other features of neurofibromatosis like café – au – lait spots, 
subcutaneous neurofibromas, axillary freckling, Lisch nodules or bony dysplasias.
Aggrawal  et  al  reported a case of a 27 year  old female with 20 intra cranial  meningiomas 
without evidence of neurofibromatosis. It is likely that all these cases belong together.
RECURRENCES IN MENINGIOMAS :
In this study, there were ten cases of recurrent meningiomas. Six of these cases were operated 
for  the  initial  tumour  at  our  Institute  while  four  cases  were  referred  from other  hospitals.  Three 
recurrent tumours occurred in the first two decades. One was a recurrent papillary meningioma in an 
intraventricular location.
The recurrences among the adult patients were more in the men with five cases compared to two 
women. All the initial lesions were WHO grade I meningiomas while two lesions had progressed to 
become WHO grade II atypical meningiomas during recurrence. There was no site predilection among 
the recurrences.
Perry et al studied 44 cases of atypical and anaplastic meningiomas and concluded that sub total 
resections,  male  gender,  and  age  less  than  40  year  are  associated  with  a  greater  likelihood  of 
recurrences2.  They  also  noted  a  higher  incidence  of  recurrent  meningiomas  being  located  in  the 
convexities.
MORBID ANATOMY
Grossly most of the specimens of meningiomas received during the study were fragmented 
specimens measuring about 10 cc on an average. The largest specimen was an atypical meningioma 
that measured about 8cms in diameter. Some cases were received with the attached duramater and three 
cases  with the adjacent  involved bone.  All  the bony specimens showed thickening as evidence of 
hyperostosis. 
The cut surface varied according to the histological type. Most cases were firm and lobulated, 
tan to brown – grey in colour. Microcystic meningiomas demonstrated tiny cysts even grossly, while 
the psammomatous meningiomas had a gritty quality while cutting.  Metaplastic meningiomas with 
xanthomatous changes had a pale yellow hue on the cut surface. There was a single case of a cystic 
meningioma with a mural nodule that proved to be a meningothelial meningioma on histopathological 
examination.
Over 75% of the cases in this study had undergone a sub total resection particularly when the 
site involved was difficult to access like the sphenoid wing or posterior cranial fossa.
HISTOPATHOLOGICAL VARIANTS OF MENINGIOMAS          
The WHO 2000 classification of meningiomas has defined fifteen variants of which nine are 
classified as WHO grade I tumours. Three WHO grade II tumours and three WHO grade III tumours 
are listed28.
Of  the  342  meningiomas  studied  during  a  five  year  period  all  the  variants  of  the  new 
classification were seen with the exception of clear cell meningiomas. WHO grade I meningiomas 
formed the largest category with 320 cases. Among these, meningothelial meningiomas were the most 
common type accounting for 128 cases.
The frontal lobes were the site most frequently involved by them, with 21 cases, followed by 
the parietal lobe with 16 cases, and sphenoid wing with 12 cases.
Among the intraventricular meningiomas, meningothelial variant accounted for a majority of 
the cases.
From the classic Russell and Rubinstein textbook, Pathology of tumours of the nervous system, 
meningothelial  meningioma  have  been  the  most  common  category.  A  review  of  936  patients  by 
Jaackelainen et al showed 43% of the cases to be syncytial meningiomas.
Table 11
HISTOLOGICAL VARIANTS 
Variants No. of Cases Percentage
Meningothelial 128 37.4%
Fibrous 77 22.51%
Transitional 47 13.74%
Psammomatous 33 9.64%
Angiomatous 23 6.72%
Lymphoplasmacytic 3 0.87%
Microcystic 4 1.16%
Secretory 1 0.29%
Metaplastic 5 1.46%
Atypical 10 2.92%
Chordoid 1 0.29%
Papillary 6 1.75%
Rhabdoid 3 0.87%
Anaplastic 1 0.29%
SITE WISE DISTRIBUTION OF MENINGOTHELIAL MENINGIOMAS 
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The histology of most of these cases were typical with whorls, sheets and nests of ill – refined 
meningothelial cells having abundant cytoplasm and vestibular nuclei with marginated chromatin.
Though a few cases exhibited pleomorphic nuclei, those without increased mitotic activity were 
still classified as meningothelial grade I meningiomas.
Fibrous  meningiomas  were  the  second  most  common  subtype.  The  frequency  of  fibrous 
meningiomas  were  found  to  increase  with  age.  There  were  25  fibrous  examples  among  the  104 
meningiomas reported in the 5th decade, and 10 cases out of the reported 47 meningiomas in the 6th 
decade.
Shah et al42 have noted a slight increase in the frequency of fibrous meningiomas with age.
Meningothelial  and fibrous  meningiomas  were found in  equal  frequency in  the  cerebello  – 
pontine angles.
Literature states that childhood meningiomas show a predominance of papillary, clear cell or 
chordoid sub types10.
Out of the 6 papillary meningiomas in our series three examples occurred in the first  three 
decades. One case presented with a recurrence, while the other two were lost to follow up.
A single case of chordoid meningioma was reported in a 46 years old male in the regions of the 
clivus. The tumour had eroded the posterior clinodal process and a partial excision was performed. 
Through the patient had a microcytic anaemia be did not have hypergamma globulinemia or associated 
castheman’s disease. The patient expired two days after surgery. 
Kepes et al described the chordoid variant of meningioma for the first time, and also stated that 
administration of steroids resulted in complete resolution of symptoms23. Couce et al in a large series of 
42 patient observed that none of their cases had systemic manifestations and that the average age of 
their patient was 47.4 years4. 
Recurrence rate is high among chordoid meningiomas which are classified as WHO grade II 
tumours.  A  possible  explanation  could  be  related  to  the  mucoid  quality  of  its  stroma  which 
mechanically facilitates the spread of the neoplastic cells. Recurrent tumours usually have an mucin 
rich chordoid pattern.
Three cases of rhabdoid meningiomas WHO grade III were reported. Two were in their sixties 
while the other was a young 17 years old female. The latter patient died a day after surgery following a 
massive epileptic attack and aspiration.
Rhabdoid meningiomas are WHO grade III and have an aggressive clinical course. Their 
histology is similar to rhabdoid tumours elsewhere in the body. There were large areas of necrosis, 
extreme cytological atypia and high mitotic counts.
Uncommonly,  rhabdoid  meningiomas  without  malignant  features  have  been  described,  the 
behaviour of these tumours being undetermined as yet.
MENINGIOMA - GRADES 
3.52%
2.92%
93.56%
Grade I
Grade II
Grade III
Atypical and Anaplastic Meningioma
          There were 10 atypical meningioma under WHO grade II meningiomas, forming 2.92% of the 
total. Two of these were recurrent lesions. They were seen with a slightly higher frequency among 
men.  No specific site predilection was noted. The age groups commonly involved were the fifth and 
sixth decades.
 A single case of anaplastic meningioma was reported in a 16 year old girl  in the posterior 
cranial fossa. The mitotic count was 30/hpf and the course was aggressive with the patient succumbing 
to the lesion 2 months after surgery.
Malhotra et al reported an incidence of 3.8% (5 out of 130) papillary meningiomas42. Atypical 
meningiomas accounted for 8.3% (32 out of 382) in a series reported by Joseph et al and only one 
malignant meningioma was encountered.
Perry et al stated the two most use ful criteria for predicting recurrences (Mayo Clinic Series) 
were brain invasion and presence of mitotic activity       (at least 4/ hpf).
Mc Carthy et al in their large series of 9000 cases determined that important prognostic factors 
for benign tumours included age at diagnosis, tumor size, surgical treatment and radiation therapy.
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Histological variants
INFERENCE 
Benign meningiomas of various histological types formed the vast  majority of cases in this 
study. Meningiomas were more common in women than men and show an increasing trend with age at 
least upto the fifth decade. Child hood meningiomas alone show a male preponderance. These tumours 
are located supratentorially in most cases.
Among the benign meningiomas meningothelial examples are the most common followed by 
fibrous, transitional and other variants. Histological grade, grade of surgical resection and adjuvant 
therapy influence survival in most cases. 
Fig.1, Meningothelial meningioma – whorled cut surface 
Fig.2, Fibrous Meningioma 
Fig.3, Transitional Meningioma 
Fig.4, Lymphoplasmacytic Meningioma 
Homogenous gray brown  cut surface 
Fig.5, Hyperostotic Parietal Bone
Fig.6, Atypical Meningioma – Showing areas of necrosis
Fig.7, Meningothelial Meningioma – Syncytial Whorls of Meningothelial Cells H&E (x 100)
Fig.8, Meningothelial Meningioma 
 Vesicular nuclei with marginated chromatin.  H&E (x 400)
Fig.9, Fibrous Meningioma - Interlacing Fascicles of thin spindle shaped cells 
H & E ( x 100)
Fig.10, Transitional Meningioma – Both syncytial islands and fibrous areas 
H & E ( x 100)
Fig.11, Psammomatous Meningioma – Numerous psammoma bodies 
H & E ( x 100)
Fig.12, Psammoma bodies - H & E ( x 400)
Fig.13, Angiomatous Meningioma – Numerous blood vessels interspersed among the 
meningothelial cells - H & E ( x 100)
Fig.14, Angiomatous Meningioma – Large caliber vessels H & E ( x 100)
Fig.15, Angiomatous Meningioma – Tumour vasculature showing lack of elastic laminae. 
Verhoeff Van Gieson (x 100)
Fig.16, Lymphoplasmacytic meningioma  
Showing dense lymphoplasmacytic infiltrate. H & E ( x 400)
Fig.17, Metaplastic Meningioma – Islands of meningothelial cells separated by mature adipose 
tissue. H & E (x 100) 
Fig.18, Metaplastic Meningioma – Lipomatous metaplasia. H & E (x 400) 
Fig.19, Microcystic Meningioma – Numerous cystic spaces of various sizes 
H & E (x 100) 
Fig.20, Microcystic Meningioma    H & E (x 400) 
Fig.21, Secretory Meningioma – PAS positive globules among small meningothelial cells groups 
PAS (x 100)
Fig.22, Chordoid Meningioma – Cords of cells with abundant cytoplasm
H & E (x 100)
Fig.23, Chordoid Meningioma – Physaliferous cells with “bubbly” cytoplasm  
H & E (x 400)
Fig.24, Chordoid Meningioma – Showing lymphoplasmacytic infiltration
H & E (x 100)
Fig.25, Chordoid Meningioma – Periodic Acid Schiff  (x 100)
Fig.26, Atypical Meningioma – Sheet like arrangement of cells 
H & E (x 100)
Fig.27, Rhabdoid Meningioma – Pleomorphic cells with abundant cytoplasm and multinucleation 
H & E (x 400)
Fig.28, Papillary Meningioma – Cellular neoplasm showing small papillae 
Fig.29, Anaplastic Meningioma – Sheet like arrangement of pleomorphic cells 
H & E (x 100)
Fig.30, Anaplastic Meningioma – Showing areas of necrosis H & E ( x 100)
SUMMARY AND CONCLUSION
The present study included 342 cases of meningiomas resected during the period from January 
2001 to August 2006. The salient features observed in this study are :
1. Meningiomas constitute 17.57% of the total 1946 central  nervous system tumours received 
during this period 
2. They formed the second largest category after gliomas.
3. The youngest and oldest patients in the study were 5 years and 78 years respectively with a 
mean age of 46 years.
4. Of  342  cases  in  the  study,  females  constituted  212  cases  (61.98%)  and  males  130  cases 
(38.01%).
5. The peak incidence was in the fifth decade with 104 cases constituting 30.40% of the total 
number of cases.
6. There were 10 meningiomas in the first decade, with a male predominance 9 cases were males 
while there was only a single female patient.
7. The most common site in the present study were the frontal lobes with 63 cases, followed by 
the parietal lobes with 62 cases.
8. Intra ventricular meningiomas which are considered rare tumours numbered 10 accounting for 
2.92% of the cases.
9. The most common presenting symptom was headache accompanied by nausea and vomiting. 
Recent onset seizures were the next most common symptom/
10. Irrespective of the histological type, the CT findings of meningiomas are usually hyperdense to 
isodense, enhancing well with contrast.
11. Benign WHO grade I meningiomas formed the overwhelming majority with 320 cases forming 
93.56% of  the  total.  Grade  II  meningiomas  numbered  11,  forming  3.52% while  grade  III 
meningiomas numbered 10 (2.92%).
12. Meningothelial meningiomas were 128 in number formed the most common histopathological 
type, (37.42%) followed by fibrous meningiomas which were 77 in number (22.51%).
13. Rare variants like secretory meningoma (1), chordoid meningioma (1),  lymphoplasmacytic 
meningiomas  (3),  microcystic  meningiomas  (4)  and   rhabdoid  meningiomas  (3)  were 
encountered during the study
The diagnosis  of  meningiomas has  always  depended upon conventional  histomorphological 
study of H & E stained sections. Categorization into various histological types and grading as per the 
guidelines of the 2000 WHO classification also is done by conventional methods. The prognosis and 
response to treatment of the various types of meningiomas well with the present system of grading. 
Ancillary  techniques  like  immunohistochemistry  and  electronmicroscopy  are  usually  not  required 
unless the tumor is very undifferentiated and anaplastic.
A lot  of  research  is  being  done  with  reference  to  meningiomas  and a  whole  host  of  new 
molecular targets like claudin, bcl – 2 etc have been discovered. Every new molecular target discovered 
prompts the search for an antibody that may help either in the diagnosis or function as a therapeutic 
agent.The future holds promise that meningiomas may be treated by non invasive methods like targeted 
molecular therapy.
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MASTER CHART
S. 
No. HPE No. Age Sex Site Histological type grade
1. 3104/ 01 46 M Para sagittal Meningothelial I
2. 3108/ 01 42 F Spinal cord Psammomatous I
3. 3114/ 01 50 M Foramen magnum Meningothelial I
4. 3119/ 01 45 F Orbit Meningothelial I
5. 3129/ 01 60 F Sphenoid wing Fibrous I
6. 3140/ 01 40 F Supra sellar Papillary III
7. 3141/ 01 45 F Para sagittal Fibrous I
8. 3154/ 01 65 M Para sagittal Meningothelial I
9. 3165/ 01 45 M Sphenoid wing Meningothelial I
10. 3167/ 01 22 M Intra ventricular Meningothelial I
11. 3168/ 01 25 M Posterior fossa Psammomatous I
12. 3172/ 01 45 F CP Angle Meningothelial I
13. 3178/ 01 35 F Frontal Meningothelial I
14. 3180/ 01 24 F Spinal cord Psammomatous I
15. 3182/ 01 40 F Para sagittal Fibrous I
16. 3192/ 01 50 M Frontal Meningothelial I
17. 3199/ 01 50 M Frontal Fibrous I
18. 3206/ 01 54 F Frontal Meningothelial I
19. 3210/ 01 38 F Para sagittal Fibrous I
20. 3212/ 01 50 M Para sagittal Fibrous I
21. 3218/ 01 45 F Orbit Meningothelial I
22. 3223/ 01 50 F Parietal Atypical II
23. 3225/ 01 65 F Para sagittal Fibrous I
24. 3231/ 01 06 M Post Fossa Angiomatous I
25. 3234/ 01 20 F Intraventricular Meningothelial I
26. 3237/ 01 28 F Para sagittal Meningothelial I
27. 3240/ 01 45 M Parietal Meningothelial I
28. 3243/ 01 35 F Para sagittal Meningothelial I
29. 3247/ 01 60 M Frontal Fibrous I
30. 3250/ 01 60 F Orbit Papillary III
31. 3253/ 01 45 F Parietal Meningothelial I
32. 3278/ 01 45 F Parietal Meningothelial I
33. 3294/ 01 52 M Parietal Meningothelial I
34. 3298/ 01 32 F Spinal cord Meningothelial I
35. 3304/ 01 45 F Spinal cord Psammomatous I
36. 3306/ 01 25 F Temporal Fibrous I
37. 3307/ 01 35 F Parietal Meningothelial I
38. 3320/ 01 40 M Frontal Meningothelial I
39. 3338/ 01 46 F Frontal Meningothelial I
40. 3342/ 01 42 M Fontal Meningothelial I
S. HPE No. Age Sex Site Histological type grade
No.
41. 3349/ 01 39 M Parietal Meningothelial I
42. 3355/ 01 34 F Frontal Meningothelial I
43. 3363/ 01 40 M Parietal Meningothelial I
44. 3373/ 01 33 F Spinal cord Meningothelial I
45. 3379/ 01 54 F Parietal Meningothelial I
46. 3383/ 01 54 M Para sagittal Meningothelial I
47. 3399/ 01 35 F Temporal Fibrous I
48. 3402/ 01 65 F Para sagittal Fibrous I
49. 3417/ 01 32 F Spinal cord Psammomatous I
50. 3428/ 01 43 M Parietal Meningothelial I
51. 3431/ 01 35 M Falx Meningothelial I
52. 3436/ 01 42 F CP Angle Fibrous I
53. 3444/ 01 30 F Parietal Meningothelial I
54. 3467/ 01 22 F CP angle Meningothelial I
55. 3474/ 01 50 F Parietal Meningothelial I
56. 3484/ 01 17 F Intraventricular Papillary III
57. 3501/ 01 35 F Spinal cord Meningothelial I
58. 3503/ 01 40 F Parietal Meningothelial I
59. 3532/02 40 M Sphenoid wing Meningothelial I
60. 3548/02 25 F CP angle Psammomatous I
61. 3568/02 30 F Parietal Meningothelial I
62. 3577/02 35 F Frontal Meningothelial I
63. 3579/02 72 M Frontal Meningothelial I
64. 3582/02 38 F Frontal Angiomatous I
65. 3585/02 18 F Frontal Angiomatous I
66. 3587/02 55 M Frontal Meningothelial I
67. 3599/02 34 F Spinal cord Psammomatous I
68. 3604/02 65 F Spinal cord Transitional I
69. 3625/02 30 F Olfactory groove Meningothelial I
70. 3637/02 06 M Spinal cord Psammomatous I
71. 3659/02 26 F Spinal cord Fibrous I
72. 3669/02 38 M Frontal Meningothelial I
73. 3666/02 53 M Temporal Angiomatous I
74. 3667/02 50 F CP angle Meningothelial I
75. 3672/02 41 M Parietal Meningothelial I
76. 3681/02 49 M Frontal Meningothelial I
77. 3683/02 50 M Falx Meningothelial I
78. 3690/02 60 F Spinal cord Psammomatous I
79. 3710/02 55 F Parietal Angiomatous I
80. 3718/02 45 M Sphenoid wing Meningothelial I
S. 
No. HPE No. Age Sex Site Histological type grade
81. 3744/ 02 35 F Sphenoid wing Transitional I
82. 3750/ 02 55 F Sphenoid wing Meningothelial I
83. 3754/ 02 20 F Spinal cord Psammomatous I
84. 3765/ 02 30 F Parietal Meningothelial I
85. 3781/ 02 43 F Falx Meningothelial I
86. 3788/ 02 06 M Parietal Meningothelial I
87. 3791/ 02 60 F Frontal Meningothelial I
88. 3799/ 02 63 M Parietal Fibrous I
89. 3803/ 02 24 F Frontal Fibrous I
90. 3805/ 02 53 M Temporal Meningothelial I
91. 3809/ 02 24 M Intraventricular Meningothelial II
92. 3820/ 02 40 F Pineal Region Meningothelial I
93. 3825/ 02 16 F Post Fossa Anaplastic III
94. 3839/ 02 45 F Falx Meningothelial I
95. 3841/ 02 70 F Temporal Meningothelial I
96. 3865/ 02 45 F Spinal cord Meningothelial I
97. 3868/ 02 54 M Para sagittal Fibrous I
98. 3869/ 02 65 F Spinal cord Psammomatous I
99. 3871/ 02 15 M Sphenoid wing Anaplastic I
100
.
3875/ 02 63 F Sphenoid wing Meningothelial I
101
.
3881/ 02 18 M Sphenoid wing Meningothelial I
102
.
3885/ 02 27 M Sphenoid wing Meningothelial I
103
.
3940/ 03 70 M Frontal Meningothelial I
104
.
3945/ 03 50 F CP angle Fibrous I
105
.
3954/ 03 10 M Para sagittal Fibrous I
106
.
3984/ 03 30 F Posterior Fossa Psammomatous I
107
.
3986/ 03 45 F Frontal Fibrous I
108
.
3988/ 03 35 F Temporal Meningothelial I
109
.
3992/ 03 54 M Parietal Transitional I
110
.
4003/ 03 42 F Posterior Fossa Meningothelial I
111
.
4013/ 03 45 M Sphenoid wing Meningothelial I
112
.
4022/ 03 40 F Frontal Meningothelial I
113
.
4028/ 03 05 F Temporal Papillary III
114
.
4035/ 03 30 F Temporal Psammomatous I
115
.
4045/ 03 29 M Sphenoid wing Meningothelial I
116
.
4050/ 03 45 M Temporal Meningothelial I
117
.
4058/ 03 45 F CP angle Meningothelial I
118
.
4059/ 03 52 F Frontal Meningothelial I
119
.
4069/ 03 39 M Frontal Meningothelial I
120
.
4070/ 03 33 M Frontal Meningothelial I
121
.
4073/ 03 40 M Parietal Meningothelial I
122
.
4094/ 03 50 F Occipital Atypical II
S. 
No. HPE No. Age Sex Site Histological type grade
123
.
4096/ 03 50 F Posterior Fossa Transitional I
124
.
4099/ 03 50 F Frontal Transitional I
125
.
4100/ 03 35 M Frontal Psammomatous I
126
.
4101/ 03 45 F Suprasellar Meningothelial I
127
.
4108/ 03 45 F Parietal Transitional I
128
.
4110/ 03 35 F Suprasellar Meningothelial I
129
.
4113/ 03 37 M Trigonal Transitional I
130
.
4123/ 03 45 F Parietal Meningothelial I
131
.
4128/ 03 63 M Suprasellar Meningothelial I
132
.
4132/ 03 10 M Frontal Metaplastic I
133
.
4133/ 03 62 M Frontal Microcystic I
134
.
4144/ 03 46 M Parietal Meningothelial I
135
.
4148/ 03 50 M Spinal cord Angiomatous I
136
.
4162/ 03 42 M Sphenoid wing Meningothelial I
137
.
4175/ 03 35 F Olfactory groove Fibrous I
138
.
4177/ 03 55 F Frontal Angiomatous I
139
.
4197/ 03 45 F Falx Fibrous I
140
.
4213/ 03 40 F Posterior Fossa Transitional I
141
.
4217/ 03 32 F Parietal Transitional I
142
.
4219/ 03 35 F Frontal Fibrous I
143
.
4236/ 03 26 F Frontal Meningothelial I
144
.
4239/ 03 30 M Falx Meningothelial I
145
.
4242/ 03 35 M Cerebellar Fibrous I
146
.
4248/ 03 50 F Falx Meningothelial I
147
.
4259/ 03 65 F Parietal Fibrous I
148
.
4265/ 03 22 F Frontal Meningothelial I
149
.
4268/ 03 40 M Parietal Transitional I
150
.
4279/03 35 F Temporal Fibrous I
151
.
4290/ 03 37 M Sphenoid wing Angiomatous I
152
.
4303/ 03 45 F Intraventricular Meningothelial I
153
.
4308/ 03 42 M Sphenoid wing Transitional I
154
.
4331/ 03 27 M Posterior Fossa Fibrous I
155
.
4353/ 03 40 F Falx Meningothelial I
156
.
4368/ 03 28 F Intraventricular Transitional I
157
.
4374/ 03 36 M Suprasellar Transitional I
158
.
4399/ 04 39 F Spinal cord Fibrous I
159
.
1324/ 04 60 F Temporal Rhabdoid III
160
.
1329/ 04 33 F Frontal Fibrous I
161
.
1336/ 04 65 F Intraventricular Transitional I
162
.
1338/ 04 30 F Spinal cord Fibrous I
163
.
1372/ 04 43 F Spinal cord Psammomatous I
164
.
1376/ 04 45 F Posterior Fossa Fibrous I
S. 
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165
.
1385/ 04 28 F Parietal Angiomatous I
166
.
1388/ 04 40 F Parietal Atypical II
167
.
1405/ 04 32 M Frontal Transitional I
168
.
1406/ 04 49 M Occipital Fibrous I
169
.
1418/ 04 60 M Spinal cord Psammomatous I
170
.
1433/ 04 21 F Cerebellar Meningothelial I
171
.
1436/ 04 40 F Frontal Fibrous I
172
.
1441/ 04 24 F Parietal Transitional I
173
.
1465/ 04 42 F Parietal Fibrous I
174
.
1473/ 04 64 M Posterior Fossa Angiomatous I
175
.
1477/ 04 35 F Spinal cord Psammomatous II
176
.
1485/ 04 43 M Frontal Atypical I
177
.
1486/ 04 27 M Posterior Fossa Meningothelial I
178
.
1487/ 04 45 M Corpus Callosum Meningothelial I
179
.
1498/ 04 44 M Sphenoid wing Atypical I
180
.
1501/ 04 41 M Intraventricular Angiomatous II
181
.
1509/ 04 22 F Frontal Atypical I
182
.
1519/ 04 45 M Parietal Meningothelial I
183
.
1522/ 04 45 F Spinal cord Meningothelial I
184
.
1530/ 04 28 F Parietal Meningothelial I
185
.
1544/ 04 35 M Spinal cord Fibrous I
186
.
1545/ 04 32 F Suprasellar Meningothelial I
187
.
1547/ 04 44 M Parietal Transitional I
188
.
1553/ 04 10 M Frontal Metaplastic I
189
.
1557/ 04 65 M CP Angle Angiomatous I
190
.
1561/ 04 45 M Frontal Transitional I
191
.
1567/ 04 16 M Sphenoid wing Transitional I
192
.
1568/ 04 19 M Parietal Angiomatous I
193
.
1587/ 04 42 F Parietal Fibrous I
194
.
1592/ 04 36 M Frontal Meningothelial I
195
.
1601/ 04 54 M Temporal Microcystic I
196
.
1608/ 04 22 F Suprasellar Meningothelial I
197
.
1611/ 04 45 M Falx Fibrous I
198
.
1622/ 04 49 M Parietal Meningothelial I
199
.
1628/ 04 48 F Spinal cord Meningothelial I
200
.
1629/ 04 48 F Frontal Transitional I
201
.
1649/ 04 43 M Parietal Microcystic I
202
.
1654/ 04 55 F CP angle Meningothelial I
203
.
1656/ 04 45 F Pineal Sol Fibrous I
204
.
1658/ 04 38 M Parietal Transitional I
205
.
1626/ 04 48 M Frontal Angiomatous I
206
.
1680/ 04 28 F Parietal Transitional I
S. 
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207
.
1690/ 04 58 M Cerebellar Meningothelial I
208
.
1691/ 04 09 M Temporal Fibrous I
209
.
1702/ 04 16 M Intraventricular Papillary III
210
.
1710/ 04 61 M Frontal Secretory I
211
.
1713/ 04 19 F Occipital Meningothelial I
212
.
1714/ 04 35 F Falx Angiomatous I
213
.
1716/ 04 45 F Falx Papillary III
214
.
1718/ 04 45 F Parietal Fibrous I
215
.
1732/ 04 19 F Occipital Meningothelial I
216
.
1736/ 04 10 M Spinal cord Psammomatous I
217
.
1739/ 04 40 M Parietal Lymphoplasmacytic I
218
.
1741/ 04 35 F Spinal cord Transitional I
219
.
1751/ 04 45 M Frontal Meningothelial I
220
.
1754/ 04 40 F Parietal Transitional I
221
.
1756/ 04 44 M Sphenoid wing Fibrous I
222
.
1759/ 04 55 F Sphenoid wing Transitional I
223
.
1773/ 04 43 M Parietal Meningothelial I
224
.
1788/ 04 45 M Orbit Fibrous I
225
.
1807/ 04 55 F Spinal cord Transitional I
226
.
1817/ 04 35 F Occipital lobe Transitional I
227
.
1822/ 04 45 M Lat. Ventricle Angiomatous I
228
.
1827/ 05 35 F Occipital lobe Meningothelial I
229
.
1838/ 05 35 F L. CP angle Fibrous I
230
.
1847/ 05 40 F Sphenoid wing Angiomatous I
231
.
1876/ 05 53 F Falx Metaplastic I
232
.
1878/ 05 40 M Sphenoid wing Fibrous I
233
.
1893/ 05 40 M Posterior Fossa Angiomatous I
234
.
1901/ 05 38 F (L) Petrous Fibrous I
235
.
1904/ 05 19 M Posterior Fossa Psammomatous I
236
.
1908/ 05 40 F Parietal Meningothelial I
237
.
1910/ 05 30 F Parietal Meningothelial I
238
.
1912/ 05 47 F Frontal Transitional I
239
.
1914/ 05 19 F Temporal Meningothelial I
240
.
1920/ 05 40 F Cerebello Pontine Transitional I
241
.
1921/ 05 39 F Frontal Angiomatous I
242
.
1955/ 05 42 M Petrous Atypical II
243
.
1959/ 05 45 F CP angle Transitional I
244
.
1961/ 05 40 F Temporal Transitional I
245
.
1974/ 05 40 F CP angle Fibrous I
246
.
1975/ 05 45 F Frontal Psammomatous I
247
.
1979/ 05 43 F Suprasellar Meningothelial I
S. 
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248
.
1982/ 05 52 F Temporal Fibrous I
249
.
1984/ 05 52 F Frontal Fibrous I
250
.
2001/ 05 55 M Spinal cord Fibrous I
251
.
2003/ 05 35 F Parietal Transitional I
252
.
2005/ 05 28 M Falx Atypical II
253
.
2016/ 05 32 F Spinal cord Psammomatous I
254
.
2017/ 05 34 M Parietal Transitional I
255
.
2025/ 05 35 M Parietal Transitional I
256
.
2033/ 05 47 F Spinal cord Psammomatous I
257
.
2035/ 05 12 M Spinal cord Meningothelial I
258
.
2038/ 05 30 F Frontal Fibrous I
259
. `
2039/ 05 25 F Spinal cord Psammomatous I
260
.
2041/ 05 55 F Ant. Clinoidal Fibrous I
261
.
2046/ 05 32 F Parietal Meningothelial I
262
.
2047/ 05 50 M CP angle Psammomatous I
263
.
2075/ 05 37 F Suprasellar Transitional I
264
.
2079/ 05 57 F Parietal Fibrous I
265
.
2082/ 05 14 F Spinal cord Meningothelial I
266
.
5090/ 05 05 M Falx Transitional I
267
.
2091/ 05 35 F Olfactory groove Transitional I
268
.
2093/ 05 52 F Falx Meningothelial I
269
.
2105/ 05 53 F Frontal Transitional I
270
.
2126/ 05 40 F Posterior Fossa Fibrous I
271
.
2127/ 05 34 F Temporal Metaplastic I
272
.
2128/ 05 35 F Frontal Meningothelial I
273
.
2160/ 05 30 F Sphenoid Meningothelial I
274
.
2162/ 05 50 M Frontal Meningothelial I
275
.
2169/ 05 60 M Occipital Rhabdoid III
276
.
2174/ 06 41 F Para sagittal Fibrous I
277
.
2178/ 06 28 F Olfactory Groove Meningothelial I
278
.
2179/ 06 27 F Olfactory Groove Metaplastic I
279
.
2188/ 06 57 F Parietal Meningothelial I
280
.
2198/ 06 40 F CP angle Meningothelial I
281
.
2216/ 06 40 F Falx Fibrous I
282
.
2229/ 06 55 F Frontal Atypical II
283
.
2249/ 06 60 M Falx Transitional I
284
.
2251/ 06 30 F CP angle CP angle I
285
.
2255/ 06 27 F Frontal Papillary III
286
.
2258/ 06 68 M Parietal Meningothelial I
287
.
2260/ 06 49 F Frontal Meningothelial I
288
.
2272/ 06 50 F Parietal Psammomatous I
S. 
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289
.
2278/ 06 21 M Frontal Fibrous I
290
.
2279/ 06 40 M Parietal Transitional I
291
.
2284/ 06 60 F Frontal Transitional I
292
.
2287/ 06 18 F Parietal Rhabdoid III
293
.
2291/ 06 60 MF Frontal Meningothelial I
294
.
2292/ 06 45 F Frontal Transitional I
295
.
2293/ 06 35 F Parietal Psammomatous I
296
.
2295/ 06 45 M Spinal Cord Fibrous I
297
.
2296/ 06 55 F Temporal Meningothelial I
298
.
2397/ 06 56 F Frontal Angiomatous I
299
.
2301/ 06 40 F Spinal Cord Psammomatous I
300
.
2308/ 06 40 F Frontal Meningothelial I
301
.
2311/ 06 55 F CP angle Fibrous I
302
.
2323/ 06 50 F Frontal Fibrous I
303
.
2338/ 06 47 F Falx Meningothelial I
304
.
2346/ 06 43 F Parietal Fibrous I
305
.
2353/ 06 56 M Falx Fibrous I
306
.
2356/ 06 40 F Spinal Cord Psammomatous I
307
.
2357/ 06 48 F Olfactory Groove Meningothelial I
308
.
2361/ 06 65 F Parietal Transitional I
309
.
2381/ 06 60 F Orbital Meningothelial I
310
.
2389/ 06 40 F Intra Ventricular Meningothelial I
311
.
2404/ 06 23 F Frontal Psammomatous I
312
.
2406/ 06 64 F Spinal Cord Lympho plasmacytic I
313
.
2416/ 06 42 M Olfactory Groove Meningothelial I
314
.
2455/ 06 46 M Falx Lympho plasmacytic I
315
.
2473/ 06 27 M Frontal Fibrous I
316
.
2475/ 06 40 F Frontal Fibrous I
317
.
2484/ 06 42 F Frontal Transitional I
318
.
2488/ 06 50 F Spinal Cord Psammomatous I
319
.
2489/ 06 41 F Temporal Fibrous I
320
.
2493/ 06 55 F Falx Transitional I
321
.
2513/ 06 60 M Parietal Micro cystic I
322
.
2514/ 06 31 M CP angle  Atypical II
323
.
2527/ 06 30 F Orbit Lympho plasmacytic I
324
.
2531/ 06 52 F Spinal Cord Psammomatous I
325
.
2524/ 06 47 M Clivus Chordoid II
326
.
2534/ 06 44 F CP angle  Transitional I
327
.
2540/ 06 45 F Petrous Fibrous I
328
.
2551/ 06 60 M Frontal Fibrous I
329
.
2556/06 50 F Petrous Fibrous I
S. 
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330
.
2558/ 06 63 F Parietal Psammomatous I
331
.
2505/ 06 51 F Sphenoid Angiomatous I
332
.
2567/ 06 50 M Spinal cord Fibrous I
333
.
2569/ 06 20 M Orbital Transitional I
334
.
2570/ 06 34 F CP angle Fibrous I
335
.
2572/ 06 25 M Posterior fossa Meningothelial I
336
.
2641/ 06 65 M Parietal Fibrous I
337
.
2652/ 06 27 M Posterior fossa Meningothelial I
338
.
2655/ 06 55 M Frontal Fibrous I
339
.
2658/ 06 65 F Falx Fibrous I
340
.
2667/ 06 26 F Parietal Fibrous I
341
.
2676/ 06 41 F Parietal Fibrous I
342
.
2680/ 06 45 F (L) CP angle Fibrous I
